跳至主要内容
临床试验/CTRI/2010/091/001229
CTRI/2010/091/001229已完成4 期

Safety Assessment of Oral Contraceptive pill containing Drospirenone & Ethinyl estradiol on Quality of life.

Glenmark Pharmaceutical Ltd0 个研究点目标入组 500 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Married females with age >18 to 40 yrs
  • Healthy women with history of normal menses or cycles [mean cycle duration of 28+/-5 days]
  • Women willing to give written Informed Consent & willing to come for follow up

排除标准

  • Hypersensitivity / contraindication to Drospirenone or any ingredients of the oral contraceptive pill
  • Pregnant and lactating women or with unexplained vaginal bleeding.
  • BMI >25 or with history of metabolic or endocrine disorders
  • History of psychoactive disease or on antidepressants
  • Aspartate aminotransferase (AST) and/or alanine -aminotransferase (ALT) 2.5 x ULN or lower
  • Serum creatinine 1.5 x ULN
  • Any condition likely to hamper compliance of the patient with the study protocol
  • Participated in a new drug study in past 3 months
  • Women with hypertension, hypercholesterolemia, diabetes
  • Women with history of smoking, myocardial infarction, stroke, peripheral vascular disease, or clotting disorders
  • Women on oral anticoagulants or prolonged use of high doses of NSAIDs

研究者

发起方
Glenmark Pharmaceutical Ltd

相似试验